ACRX Share Price

Open 3.10 Change Price %
High 3.15 1 Day 0.00 0.00
Low 3.07 1 Week 0.10 3.33
Close 3.10 1 Month 0.05 1.64
Volume 216137 1 Year 0.03 0.98
52 Week High 4.08
52 Week Low 2.40
ACRX Important Levels
Resistance 2 3.17
Resistance 1 3.14
Pivot 3.11
Support 1 3.06
Support 2 3.03
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
FTR 2.02 2.02%
FTR 2.02 2.02%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.75 16.67%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.10 100.00%
VALV 0.04 100.00%
PTSX 0.21 90.91%
LOCM 0.09 50.00%
QKLS 0.15 50.00%
PFMT 2.41 31.69%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)

ACRX Technical Analysis 1.5
As on 29th Mar 2017 ACRX Share Price closed @ 3.10 and we RECOMMEND Sell for LONG-TERM with Stoploss of 3.12 & Buy for SHORT-TERM with Stoploss of 2.97 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACRX Target for March
1st Target up-side 3.4
2nd Target up-side 3.65
3rd Target up-side 3.9
1st Target down-side 2.7
2nd Target down-side 2.45
3rd Target down-side 2.2
ACRX Other Details
Segment EQ
Market Capital 65612500.00
Sector Healthcare
Industry Medical Appliances & Equipment
Offical website http://www.acelrx.com
ACRX Address
ACRX
351 Galveston Drive
Redwood City, CA 94063
United States
Phone: 650-216-3500
Fax: 650-216-6500
ACRX Latest News
Interactive Technical Analysis Chart AcelRx Pharmaceuticals, Inc. ( ACRX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on AcelRx Pharmaceuticals, Inc.
ACRX Business Profile
AcelRx Pharmaceuticals, Inc., incorporated on July 13, 2005, is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company has completed Phase 2 clinical development for two additional product candidates, the Sufentanil NanoTab BTP Management System, or ARX-02, for the treatment of cancer breakthrough pain (BTP), and the Sufentanil/Triazolam NanoTab, or ARX-03, designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. The Company is preparing to initiate two Phase 3 clinical trials for its product candidate, the Sufentanil NanoTab PCA System, or ARX-01. Its operations are based in Redwood City, California.